US 8158581
IGF-1 fusion polypeptides and therapeutic uses thereof
granted A61KA61K38/30A61P
Quick answer
US patent 8158581 (IGF-1 fusion polypeptides and therapeutic uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K38/30, A61P, A61P19/10, A61P21/00